News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,757 Results
Type
Article (13936)
Company Profile (101)
Press Release (250720)
Section
Business (88355)
Career Advice (465)
Deals (15405)
Drug Delivery (66)
Drug Development (36750)
Employer Resources (50)
FDA (6302)
Job Trends (6274)
News (150721)
Policy (14071)
Tag
Academia (440)
Alliances (23276)
Alzheimer's disease (376)
Approvals (6324)
Artificial intelligence (86)
Bankruptcy (146)
Best Places to Work (4432)
Breast cancer (69)
Cancer (506)
Cardiovascular disease (52)
Career advice (407)
Cell therapy (79)
Clinical research (30865)
Collaboration (274)
Compensation (114)
COVID-19 (755)
C-suite (90)
Data (500)
Diabetes (66)
Diagnostics (1311)
Drug discovery (46)
Drug pricing (60)
Earnings (31868)
Events (37261)
Executive appointments (310)
FDA (6617)
Funding (172)
Gene therapy (84)
GLP-1 (322)
Government (1286)
Healthcare (3565)
Infectious disease (782)
Inflammatory bowel disease (52)
Interviews (58)
IPO (5891)
Job creations (2068)
Job search strategy (373)
Layoffs (178)
Legal (3436)
Lung cancer (71)
Manufacturing (122)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9653)
Metabolic disorders (210)
Neuroscience (522)
NextGen: Class of 2025 (1605)
Non-profit (596)
Northern California (609)
Obesity (122)
Opinion (121)
Patents (86)
People (28869)
Pharmaceutical (65)
Phase I (8084)
Phase II (13055)
Phase III (11700)
Pipeline (272)
Policy (52)
Postmarket research (1403)
Preclinical (3198)
Radiopharmaceuticals (118)
Rare diseases (141)
Real estate (2648)
Regulatory (10027)
Research institute (567)
Resumes & cover letters (55)
Southern California (599)
Startups (1644)
United States (5975)
Vaccines (133)
Weight loss (88)
Date
Last 7 days (233)
Last 30 days (996)
Last 365 days (12407)
2025 (1729)
2024 (12557)
2023 (14315)
2022 (19629)
2021 (20167)
2020 (19113)
2019 (14946)
2018 (11788)
2017 (14017)
2016 (13215)
2015 (15578)
2014 (12448)
2013 (10596)
2012 (11403)
2011 (11927)
2010 (10889)
Location
Africa (317)
Arizona (46)
Asia (20027)
Australia (2594)
California (1450)
Canada (790)
China (185)
Colorado (60)
Connecticut (61)
Europe (39228)
Florida (250)
Illinois (165)
Indiana (113)
Japan (72)
Kansas (53)
Maryland (214)
Massachusetts (1217)
Minnesota (78)
New Jersey (608)
New York (405)
North Carolina (340)
Northern California (609)
Pennsylvania (363)
South America (505)
Southern California (599)
Texas (185)
Virginia (57)
Washington State (100)
264,757 Results for "kite pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Business
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
Cellares today announced that Kite , a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle.
June 27, 2024
·
2 min read
Press Releases
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
December 10, 2024
·
19 min read
Business
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL).
June 3, 2024
·
19 min read
Biotech Beach
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
June 3, 2024
·
14 min read
Press Releases
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 10, 2024
·
18 min read
Biotech Bay
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Arcellx, Inc. and Kite, a Gilead Company, announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.
May 9, 2024
·
9 min read
Biotech Bay
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.
May 9, 2024
·
9 min read
BioForest
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology Annual Meeting.
May 7, 2024
·
42 min read
FDA
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
The new FDA-approved manufacturing process for Kite’s CAR-T cell therapy Yescarta will allow a 14-day turnaround compared to 16 days, the company announced on Tuesday.
January 31, 2024
·
1 min read
·
Tyler Patchen
1 of 26,476
Next
